Eyenovia Announces Rebranding and Corporate Name Change to Hyperion DeFi Inc.
Eyenovia announced a rebrand to Hyperion DeFi Inc., signaling a pivot toward decentralized finance. The rebranding reflects Hyperion DeFi’s cryptocurrency treasury reserve strategy, centered around HYPE, the native token of the Hyperliquid blockchain and decentralized exchange.
Effective July 3, 2025, the company’s common stock will trade under the new ticker symbol “HYPD” on the Nasdaq Capital Market.
“Our new identity as Hyperion DeFi, Inc. represents the next evolution of our business and a firm commitment to integrating blockchain technology into our treasury strategy,” Michael Rowe, CEO of Hyperion DeFi, said in a company news release. “The name ‘Hyperion’ — inspired by the tallest known living tree — reflects our ambition to become the largest holder of HYPE globally, and ultimately one of the most prominent digital treasury vehicles in the public markets.”
The rebranding and refocus of the company comes after recent corporate setbacks for Eyenovia in eye care. In November, the company announced that its phase 3 CHAPERONE study failed to meet its primary endpoint. The study was investigating Eyenovia’s proprietary drug-device combination, using low-dose atropine dispensed through the company's Optejet platform, as a potential treatment for pediatric progressive myopia. In January, the company completed an 1-80 reverse stock split in order to regain compliance with the minimum bid price required to remain listed on the Nasdaq Capital Market. In February, Eyenovia announced a debt restructuring to defer all interest as well as principal redemption payments through September 2025.
The company is the first publicly traded US firm to strategically acquire and stake HYPE tokens, offering investors indirect exposure to a leading DeFi ecosystem, according to a company news release. According to Mr. Rowe, the move also complements ongoing efforts to commercialize Eyenovia’s flagship Optejet User Filled Device (UFD), a next-generation ophthalmic dispenser designed to enhance patient compliance and safety in front-of-the-eye treatments.
“We see this as a dual innovation strategy,” said Hyunsu Jung, Chief Investment Officer. “Just as the poem ‘Hyperion’ by John Keats depicts a transfer of power from old gods to new, we believe the rise of blockchain and decentralized exchanges marks a new era in finance. Hyperion DeFi is positioned to lead that transition.”
To operationalize its crypto engagement, the company also launched a co-branded validator node, “Kinetiq x Hyperion,” and has begun staking its HYPE holdings to generate yield while preparing for deeper onchain participation.